Mydecine Innovations Group Inc. announced Damon Michaels, Josephine Wu, Dr. Saeid Babaei and Dr. Victoria Hale have recently resigned as directors of the Company. The departures are part of a large organizational shift that will allow the corporation to concentrate on its core competencies with more efficiency. Michaels will continue to serve as Chief Operating Officer for the organization.

As a result of the resignations, the Company is currently searching for candidates with a background in drug development to fill two board positions.